Article
Oncology
Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Summary: The ICONIC trial evaluated the clinical efficacy and safety of the investigational ICOS agonist vopratelimab, identifying pharmacodynamic biomarkers and potential predictive biomarkers associated with the drug.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Eider Moreno-Cortes, Pedro Franco-Fuquen, Juan E. Garcia-Robledo, Jose Forero, Natalie Booth, Januario E. Castro
Summary: Anti-ROR1 CAR T-cells activated by ICOS.OX40 tandem co-stimulation show enhanced targeted cytotoxicity in vitro and in vivo, associated with a phenotype that promotes T-cell persistence.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Alessio Cirillo, Ilaria Grazia Zizzari, Andrea Botticelli, Lidia Strigari, Hassan Rahimi, Simone Scagnoli, Fabio Scirocchi, Angelina Pernazza, Angelica Pace, Bruna Cerbelli, Giulia d'Amati, Paolo Marchetti, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
Summary: Pembrolizumab has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. This study suggests that circulating CD137(+) T cells may serve as biomarkers for predicting the response of patients to pembrolizumab treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Sophie Postel-Vinay, Vincent K. Lam, Willeke Ros, Todd M. Bauer, Aaron R. Hansen, Daniel C. Cho, F. Stephen Hodi, Jan H. M. Schellens, Jennifer K. Litton, Sandrine Aspeslagh, Karen A. Autio, Frans L. Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M. Paul, Christoph M. Ahlers, Helen Zhou, Herbert Struemper, Shelby A. Gorman, Maura Watmuff, Kaitlin M. Yablonski, Niranjan Yanamandra, Michael J. Chisamore, Emmett Schmidt, Axel Hoos, Aurelien Marabelle, Jeffrey S. Weber, John Heymach
Summary: The ENGAGE-1 study evaluated the use of GSK3174998, an OX40 agonistic monoclonal antibody, alone or in combination with pembrolizumab in patients with advanced solid tumors. The combination therapy demonstrated good safety and tolerability, but limited clinical activity, suggesting that further development may not be warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Sebastian Wimmer, Lisa Deloch, Michael Hader, Anja Derer, Fridolin Grottker, Thomas Weissmann, Markus Hecht, Antoniu-Oreste Gostian, Rainer Fietkau, Benjamin Frey, Udo S. Gaipl
Summary: Following radiotherapy, the HPV status may not distinctly predict immunological responses, highlighting the importance of individualized ICM expression in selecting patients for targeted immune therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Chiara Valentini, Nadja Ebert, Lydia Koi, Manuel Pfeifer, Steffen Loeck, Christoph Erdmann, Mechthild Krause, Michael Baumann
Summary: This study aimed to compare the efficacy of fractionated radiotherapy versus radiochemotherapy with cisplatin in HPV-positive and negative human head and neck squamous cell carcinoma xenografts. The results showed that RCT significantly increased local tumor control in two out of three HPV-positive tumor models and one HPV-negative tumor model. In the pooled group of all HPV-positive tumors, RCT substantially enhanced local tumor control, while this effect was not observed in HPV-negative tumors.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Elizabeth Repash, Drasti Kanakia, Jun Ma, Julia Kristensson, Fanglei You, Carly Campbell, David Witty, Mike Kelly, Stephen Blakemore, Phil Jeffrey, Kevin McDonnell, Philip Brandish, Nicholas Keen
Summary: The study developed a tumor-targeted CD137 agonist BT7480 that binds to Nectin-4 and CD137, resulting in potent tumor-specific immune cell activation, showing potential therapeutic effects in human cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Suji Udayakumar, Ambica Parmar, Natasha B. Leighl, Louis Everest, Vanessa S. Arciero, Seanthel Delos Santos, Amanda Rahmadian, Mark K. Doherty, Kelvin K. W. Chan
Summary: Pembrolizumab monotherapy has replaced chemotherapy as the first-line treatment for patients with metastatic non-small cell lung cancer with tumor programmed death-ligand 1 expression > 50%. The benefit of chemotherapy combined with pembrolizumab remains uncertain and further research is needed.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Xiaobin Shang, Wencheng Zhang, Gang Zhao, Fei Liang, Chen Zhang, Jie Yue, Xiaofeng Duan, Zhao Ma, Chuangui Chen, Qingsong Pang, Weihong Zhang, Liang Liu, Xiubao Ren, Bin Meng, Peng Zhang, Yegang Ma, Lin Zhang, Hecheng Li, Xiaozheng Kang, Yin Li, Hongjing Jiang
Summary: This study aims to compare the efficacy and safety of pembrolizumab combined with neoadjuvant chemotherapy and chemoradiotherapy versus neoadjuvant chemotherapy and chemoradiotherapy alone for locally advanced resectable esophageal squamous cell carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xinyi Zhang, Mengyu Rui, Chao Lin, Zhi Li, Dongliang Wei, Ruxue Han, Houyu Ju, Guoxin Ren
Summary: This study evaluated the prognostic value of body mass index (BMI) in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab. The results showed that BMI was significantly correlated with overall survival time and progression-free survival time. Underweight patients had worse clinical prognosis compared to normal weight patients.
Review
Cardiac & Cardiovascular Systems
Lina Su, Chuanfen Liu, Wenjie Wu, Yuxia Cui, Manyan Wu, Hong Chen
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but their cardiotoxicity is a rare but concerning side effect. This case report describes an 80-year-old patient with head and neck squamous cell cancer who developed myocarditis and complete atrioventricular block (CAVB) after receiving pembrolizumab treatment. The patient responded well to high-dose steroid therapy and had a good prognosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Oncology
Minjiang Chen, Yan Xu, Jing Zhao, Xiaoyan Liu, Xiangning Liu, Dongming Zhang, Yuequan Shi, Li Zhang, Wei Zhong, Mengzhao Wang
Summary: The efficacy of immune checkpoint inhibitors for EGFR-mutant NSCLC is worth investigating. Propensity score matching showed that chemotherapy plus immunotherapy improved progression-free survival compared to chemotherapy alone, suggesting its potential usefulness for patients with EGFR-mutant NSCLC.
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Mingjia Li, Songzhu Zhao, Gabrielle Lopez, Austin Secor, Parthib Das, Nitya Surya, Madison Grogan, Sandip Patel, Karthik Chakravarthy, Abdul Miah, Daniel Spakowicz, Gabriel Tinoco, Zihai Li, Lai Wei, Kai He, Erin Bertino, Asrar Alahmadi, Regan Memmott, Jacob Kaufman, Peter G. Shields, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Dwight H. Owen
Summary: This study investigated the association between the change in mean platelet volume (MPV) and survival as well as the risk of developing immune-related adverse events (irAEs) in patients with metastatic non-small cell lung cancer (NSCLC) who received first-line immune checkpoint inhibitors (ICIs). The study found that a decrease in MPV was associated with higher survival rates, while a decrease in MPV was associated with a higher risk of developing irAEs.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hasan Alsaid, Shih-Hsun Cheng, Meixia Bi, Fang Xie, Mary Rambo, Tinamarie Skedzielewski, Bao Hoang, Sunish Mohanan, Debra Comroe, Andrew Gehman, Chih-Yang Hsu, Kamyar Farhangi, Hoang Tran, Valeriia Sherina, Minh Doan, M. Reid Groseclose, Christopher B. Hopson, Sara Brett, Ian A. Wilson, Andrew Nicholls, Marc Ballas, Jeremy D. Waight, Beat M. Jucker
Summary: The study utilized immuno-PET imaging to investigate the dynamics of CD8(+) T cell infiltration in tumors following ICOS agonist and PD-1 blocking antibody therapy. The results demonstrated the enhanced spatial and temporal resolution of CD8(+) T cell infiltration across tumors and lymphoid tissues using this technique.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Oncology
Danny Rischin, Kevin J. Harrington, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey-Long Hong, Rene Gonzalez Mendoza, Liyi Jia, Diana Chirovsky, Josephine Norquist, Fan Jin, Barbara Burtness
Summary: This study assessed the impact of pembrolizumab alone and in combination with chemotherapy on the quality of life in patients with recurrent or metastatic head and neck squamous cell carcinoma. The results showed that pembrolizumab monotherapy and combination therapy with chemotherapy extended overall survival while maintaining stable health-related quality of life.
